Multiple traumatic neuromas after laser ablation treatment for viral warts

Gye, Jiwon; Nam, Chanhee; Kim, Ji Seok; Kim, Jee Young; Hong, Soon-Tae; Park, Byung Cheol; Kim, Myung‐Hwa

doi:10.1111/1346-8138.12319

Cited by 2 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ablative techniques involve curettage with scalpel, lazer or freezing (Ferenczy, Behelak et al, 1995; Wollina, Konrad et al, 2001; Oni & Mahaffey, 2011; Khandelwal, Bumb et al, 2013); topical cytotoxic treatments include salicylic acid, trichloroacetic acid, acyclic nucleosides, podophyllotoxin, and photodynamic treatments (Snoeck, 2006); immunomodulators include interferon A, contact sensitizers such as dichlorobenzene and innate immune activators such as imiquimod (Schofer, Van et al, 2006; Gallagher & Derkay, 2009). In general, the treatments show modest levels of efficacy (clinical outcomes summarized recently in (Kwok, Gibb et al, 2012)), and include several side effects as well as recurrences (Gye, Nam et al, 2013). Improved outcomes are noted in combination treatment approaches (Kaspari, Gutzmer et al, 2002; Lu, Yang et al, 2012; Xu, Xiang et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Formulation of cidofovir improves the anti-papillomaviral activity of topical treatments in the CRPV/rabbit model

Christensen

Cladel

et al. 2014

Antiviral Research

View full text Add to dashboard Cite

Current topical treatments for papillomas use ablative, cytotoxic and immunomodulating strategies and reagents. However, the effectiveness of topical treatments using different formulations has not been examined in preclinical models or clinical trials. The purpose of this study was to determine whether formulation of the small molecule acyclic nucleoside, cidofovir (CDV), could lead to improved therapeutic endpoints following topical treatment of papillomas using the cottontail rabbit papillomavirus (CRPV)/rabbit model. Different formulations with a set dose of 1% cidofovir were tested to establish comparative data. The results demonstrated that anti-papilloma treatments with topical CDV were greatly enhanced when formulated versus unformulated. Best results were obtained with CDV formulated in cremophor, then in carbomer 940, and then in DMSO. Further studies indicated that effective formulations led to complete cures of papillomas at dilutions less than 0.3% CDV. These studies together with previous observations demonstrated that unformulated CDV under the same treatment regime required doses of 2% to achieve cures demonstrating that much less compound can be used when properly formulated.

show abstract